GLP-3 (retatrutide) Research
Triple GLP-1/GIP/Glucagon Receptor Agonist
Research area: metabolic signaling research
Retatrutide is an investigational triagonist peptide studied for simultaneous activity at GLP-1, GIP, and glucagon receptors. It is one of the most closely watched compounds in current metabolic research, with Phase 2 trial results published in the New England Journal of Medicine in 2023.
Research Areas
Triple Receptor Agonism Research
Studies investigate how simultaneous agonism at GLP-1, GIP, and glucagon receptors may influence metabolic signaling cascades differently than single or dual receptor agents. Retatrutide is considered a 'triagonist' in this research context.
Metabolic Signaling Pathways
Phase 2 research (the TRIUMPH-4 trial, NCT05071326) examined effects on body weight and cardiometabolic markers in adult populations over 48 weeks. Findings were published in the New England Journal of Medicine in 2023.
Incretin Hormone Research
Researchers investigate retatrutide's role in hypothalamic appetite-signaling pathways and its interactions with the incretin hormone system — the GLP-1, GIP, and glucagon axis — that regulate energy balance and glucose homeostasis.
Cardiovascular & Metabolic Marker Research
Ongoing trials examine changes in lipid profiles, liver fat, blood pressure, and other cardiometabolic markers in the context of triagonist signaling pathway research.
Investigational compound; not FDA-approved. Research is ongoing in Phase 3 trials.
Research References
Discuss any health concerns with a licensed clinician before making health decisions.
Have questions about GLP-3 (retatrutide)?
Request a free consultation to ask questions and learn more about this research area.
Affiliate disclosure: I am an independent affiliate of The Longevity Consultants and may receive compensation if you request a consultation through me.
Request a free consultation